Vaccinology in the post-COVID-19 era.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
19 01 2021
Historique:
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 16 1 2021
Statut: ppublish

Résumé

The COVID-19 pandemic is a shocking reminder of how our world would look in the absence of vaccination. Fortunately, new technologies, the pace of understanding new and existing pathogens, and the increased knowledge of the immune system allow us today to develop vaccines at an unprecedented speed. Some of the vaccine technologies that are fast-tracked by the urgency of COVID-19 may also be the answer for other health priorities, such as antimicrobial resistance, chronic infections, and cancer, that the post-COVID-19 world will urgently need to face. This perspective analyzes the way COVID-19 is transforming vaccinology and the opportunities for vaccines to have an increasingly important role in health and well-being.

Identifiants

pubmed: 33431690
pii: 2020368118
doi: 10.1073/pnas.2020368118
pmc: PMC7826410
pii:
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: All authors are full-time employees of the GlaxoSmithKline group of companies. This work was sponsored by GlaxoSmithKline Biologicals SA.

Références

Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Sci Transl Med. 2013 May 15;5(185):185ra68
pubmed: 23677594
Science. 1993 Mar 19;259(5102):1745-9
pubmed: 8456302
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Sci Transl Med. 2018 Aug 29;10(456):
pubmed: 30158151
J Exp Med. 2016 Apr 4;213(4):469-81
pubmed: 27022144
Curr Opin Microbiol. 2000 Oct;3(5):445-50
pubmed: 11050440
Nature. 1992 Mar 12;356(6365):152-4
pubmed: 1545867
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Sci Transl Med. 2011 Jul 13;3(91):91ra62
pubmed: 21753121
N Engl J Med. 2013 May 16;368(20):1888-97
pubmed: 23577628
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Mol Ther. 2019 Apr 10;27(4):757-772
pubmed: 30803823
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9
pubmed: 22908294
Semin Immunol. 2018 Oct;39:14-21
pubmed: 29801750
NPJ Vaccines. 2018 Oct 10;3:51
pubmed: 30323958
Science. 2000 Mar 10;287(5459):1816-20
pubmed: 10710308
Nat Rev Immunol. 2002 Sep;2(9):706-13
pubmed: 12209139
Vaccine. 2001 Mar 21;19(17-19):2673-80
pubmed: 11257408
Vaccine. 2012 Feb 21;30(9):1729-36
pubmed: 22192849
Lancet. 1992 Jun 13;339(8807):1429-32
pubmed: 1351126
Science. 1990 Mar 23;247(4949 Pt 1):1465-8
pubmed: 1690918
Nature. 2020 Oct;586(7827):127-132
pubmed: 32866963
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12868-12871
pubmed: 30559204
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4055-4059
pubmed: 28396438
N Engl J Med. 2019 Dec 19;381(25):2429-2439
pubmed: 31661198
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Vaccines (Basel). 2020 Aug 22;8(3):
pubmed: 32842669
Science. 2019 Aug 2;365(6452):505-509
pubmed: 31371616
N Engl J Med. 2005 Jun 2;352(22):2271-84
pubmed: 15930418
Emerg Microbes Infect. 2013 Aug;2(8):e52
pubmed: 26038486
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
JAMA. 2013 Apr 3;309(13):1368-78
pubmed: 23549582
Eur J Immunol. 1993 Jul;23(7):1719-22
pubmed: 8325342
FEBS Lett. 2006 May 22;580(12):2985-92
pubmed: 16716781
N Engl J Med. 2020 Jan 23;382(4):309-317
pubmed: 31971676
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373

Auteurs

Rino Rappuoli (R)

Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy; rino.r.rappuoli@gsk.com.

Ennio De Gregorio (E)

Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy.

Giuseppe Del Giudice (G)

Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy.

Sanjay Phogat (S)

Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy.

Simone Pecetta (S)

Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy.

Mariagrazia Pizza (M)

Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy.

Emmanuel Hanon (E)

Research and Development Centre, GlaxoSmithKline (GSK), 1330 Rixensart, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH